TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06145620

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: The intervention involves the visualization of different videos explaining the performance of lumbar strengthening exercises, measures for back care, and neuroscience pain education.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: The intervention involves the visualization of different videos explaining the performance of lumbar strengthening exercises, measures for back care, and neuroscience pain education.
Study: NCT04857320

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Human insulin
Description: Human Insulin from recombinant source delivered in a solution capable of enabling transdermal delivery formulated at 100 IU/mL of delivery vehicle.
Study: NCT04761224

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluido® Irrigation Fluid Heater System
Description: Patients in the Heated group will benefit from intraoperative warming by means of NaCl bags instilled using the Fluido® Irrigation warming cassette and with the use of specific instillation tubing (SEBAC laboratory, Set URO Fluido® Irrigation): this device allows continuous and precise heating of the solution with an instillation temperature of 38-39°C.
Study: NCT06522022

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally Responsive SBIRT for OB
Description: SBIRT is a well-established enhanced screening preventive intervention model that is feasible and acceptable for use with trauma-exposed patients and in minoritized communities and can be delivered in the OB clinic during a prenatal care visit. The elements include:~1. standardized screening for PTSD and depression using the Primary Care Post Traumatic Stress Disorder Screen (PC-PTSD-5) and the Edinburgh Postnatal Depression Screening (EPDS) that will mirror brief screening practice;~2. explicit focus on concerns regarding mistrust,~3. psychoeducation on PTSD, depression, and the effects of trauma including medical trauma and traumatic loss on health/functioning,~4. motivational interviewing strategy components to promote awareness of psychological symptoms and engagement in culturally relevant resources including support/resources related to relevant social determinants of health,~5. teaching coping skills with culturally responsive technology tools

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Screening for PTSD
Description: This well-established 5-minute in-clinic interview includes administration of the PC-PTSD-5, a 5-item PTSD screening tool by trained medical staff (nurse, physician's assistant). Providers receive approximately one hour of training in trauma-informed care and how to administer the screening protocol. This method is regularly used in primary care clinic settings with trauma-exposed veterans and is validated for use in civilian samples, including low-income Black adults utilizing urban safety net hospital medical clinics.
Study: NCT05576636

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulation training
Description: Expectations regarding the scenario were explained to the participants before the implementation. They were given information about the standard patient. Roles were distributed, and the implementation time of the scenario was announced. Written permission was obtained from students involved in the scenario. The intervention group was given scenario-based education appropriate for the approach to a standard patient with COVID-19. During the implementation of the scenario, the instructor did not interfere with students, and after the feedback, the show-do method was used to improve the incorrect skill steps. Two instructors evaluated students' performance on the standard patient simulation as achieved-failed and the application was recorded as a pre-test.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: The control group didn't apply any interference during the study. Participants in the control group continued their routine follow-up.
Study: NCT04910997

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Description: Combination of supervised and home-based aerobic exercise training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise training
Description: Combination of supervised and home-based aerobic exercise training
Study: NCT04555616

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Environmental Design
Description: Participants' caregivers will receive set script of physical environmental modifications (i.e., declutter living space, reduce background noise, increase natural light), and social environment training script will include caregiving techniques: training for calming demeanor (emotional contagion), needs-driven care to decrease behavioral disruption, and accepting and accommodating approach to behavioral disruption. A pre-selected sensory stimulation kit will be provided to each participants' caregiver for administration throughout the day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Environmental Design
Description: Participants' caregivers will receive set script of physical environmental modifications and social environment training script in a standard protocol. Following initial assessments, individualized sensory stimulation kits will be developed using subjects' preferred sensory stimuli (as determined by the Adult Sensory Profile assessment and informant report) and will be provided via caregiver administration throughout the day to promote maintained behavioral regulation.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants' caregivers will receive a set script of placebo modifications.
Study: NCT05631613

Intervention type: PROCEDURE
Intervention: cTACE(conventional transarterial chemoembolization)
Description: transarterial chemoembolization with lipiodol-idarubicin emulsion

Intervention type: PROCEDURE
Intervention: cTACE(conventional transarterial chemoembolization)
Description: transarterial chemoembolization with lipiodol-idarubicin emulsion
Study: NCT06216509

Intervention type: DEVICE
Group type: OTHER
Intervention: Endoscopic ultrasound pressure measurement
Description: all eligible patients from both groups will undergo Endoscopic ultrasound pressure measurement under sedation.

Intervention type: DEVICE
Group type: OTHER
Intervention: Endoscopic ultrasound pressure measurement
Description: all eligible patients from both groups will undergo Endoscopic ultrasound pressure measurement under sedation.
Study: NCT05322473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonelokimab (M1095)
Description: randomized treatment; parallel-group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonelokimab (M1095)
Description: randomized treatment; parallel-group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: randomized treatment; parallel-group

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: randomized treatment; parallel-group
Study: NCT05062499

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active TENS
Description: electrical stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TENS
Description: no stimulation
Study: NCT05593068

Intervention type: PROCEDURE
Intervention: MRI
Description: Pancreatic MRI
Study: NCT05684211

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ametumumab
Description: A recombinant fully human anti-EGFR monoclonal antibody

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ametumumab
Description: A recombinant fully human anti-EGFR monoclonal antibody

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ametumumab
Description: A recombinant fully human anti-EGFR monoclonal antibody

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-PD-1 monoclonal antibody
Description: Toripalimab 3 mg/kg，Intravenous titration，Q2W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-PD-1 monoclonal antibody
Description: Toripalimab 3 mg/kg，Intravenous titration，Q2W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Cetuximab 500 mg/m2 ，Intravenous titration，Q2W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI
Description: Rinotecan hydrochloride，180mg/m2，intravenous titration，Q2W； 5 -Fluorouracil，400 mg/ m2, intravenous push, then 1200 mg/ m2 /day x 2 days, intravenous titration,Q2W; Calcium folinate,400mg/m2,intravenous titration，Q2W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI
Description: Rinotecan hydrochloride，180mg/m2，intravenous titration，Q2W； 5 -Fluorouracil，400 mg/ m2, intravenous push, then 1200 mg/ m2 /day x 2 days, intravenous titration,Q2W; Calcium folinate,400mg/m2,intravenous titration，Q2W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI
Description: Rinotecan hydrochloride，180mg/m2，intravenous titration，Q2W； 5 -Fluorouracil，400 mg/ m2, intravenous push, then 1200 mg/ m2 /day x 2 days, intravenous titration,Q2W; Calcium folinate,400mg/m2,intravenous titration，Q2W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI
Description: Rinotecan hydrochloride，180mg/m2，intravenous titration，Q2W； 5 -Fluorouracil，400 mg/ m2, intravenous push, then 1200 mg/ m2 /day x 2 days, intravenous titration,Q2W; Calcium folinate,400mg/m2,intravenous titration，Q2W
Study: NCT05335421

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Minds Program (HMP) App
Description: The full HMP app includes 5 modules with practices designed to cultivate categories of mental and emotional skills linked to both hedonic and eudaimonic well-being. These include the cultivation of mindful attention (Awareness), positive relationships with self and others (Connection), insight into the nature of self and internal experience (Insight), and purpose, values, and meaning in life (Purpose), as well as an initial module which includes abbreviated introductions to the topics and lessons in all four areas (Foundations). For this study, the active intervention will include 4 weeks of training using the Foundations module followed by 4 weeks of training using the Awareness module.
Study: NCT06364488

Intervention type: DEVICE
Group type: OTHER
Intervention: TrueBlue App
Description: The use of the TrueBlue App, to generate automated measures of mood that can be assessed for agreement with validated clinical scales eg. PHQ9.
Study: NCT06326567

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: C4 Program
Description: C4 program aims to provide a multi-level intervention program (Patient Level, Healthcare Team and Healthcare System Level) that improves the coordination of care with supportive/ancillary care providers and community services through the use of patient navigation and a digital needs assessment and a closed-loop referral system and improves patient-centered communication and engagement in care through skills training for the healthcare team and provision of culturally appropriate patient educational tools and resources. The program components incorporate three areas that are critical to improving patient-centered care: coordination of care, patient-centered communication and engagement, and psychosocial care and other supportive services.
Study: NCT05078840

Intervention type: OTHER
Intervention: Evaluation of first line treatment in patients with stage I and II LBCL
Description: Evaluation of first line treatment in patients with stage I and II LBCL, without poor prognostic factors with treatment adapted to PET-CT after 3 R-CHOP
Study: NCT04896515

Intervention type: DIETARY_SUPPLEMENT
Intervention: Supplemental parenteral nutrition
Description: Supplemental parenteral nutrition OLIMEL N12E (Baxter Healthcare Corporation)
Study: NCT05067699

Intervention type: DIAGNOSTIC_TEST
Intervention: Human 25-Hydroxyvitamin D3 (HVD3) ELISA Kit (96 well)
Description: The serum will be tested by a double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) to assay the level of Human 25Dihydroxy vitamin D（25-OH-D).

Intervention type: DIAGNOSTIC_TEST
Intervention: Human 25-Hydroxyvitamin D3 (HVD3) ELISA Kit (96 well)
Description: The serum will be tested by a double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) to assay the level of Human 25Dihydroxy vitamin D（25-OH-D).
Study: NCT05982405

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training group: Inspiratory muscle training
Description: The individuals in the training group will be performed inspiratory muscle training at 30-50% of the maximal inspiratory pressure. Inspiratory muscle training will be done using an inspiratory muscle training device (PowerBreathe®) that works with the threshold loading principle. Inspiratory muscle training will be done for 15 minutes per a session, 2 times per a day or, if tolerated, 30 minutes per a day and 1 time per a day, 5-7 days/week (one session under the supervision and the others at home), for a total of 6 weeks. Applications made at home will be followed with a diary.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control group: Thoracic expansion exercise
Description: Individuals in the control group will be performed thoracic expansion exercises. Thoracic expansion exercises will be applied to individuals in an upright sitting position. In this position, individuals will place their hands on their lower ribs and then perform the cycle of deep breathing + holding the deep breath for 3 seconds + slowly emptying all the breath 3 times in a row. After this cycle, individuals will be asked to rest by taking 3-4 calm breaths. Immediately after, the individual will be asked to repeat the same cycle and repeat the cycle with calm breaths and rest until it reaches 10 repetitions. The individual will do this session 4 times a day. Individuals will do the first session of breathing exercises under supervision. In this way, incorrect exercise will be prevented. Other breathing exercise sessions will be done by individuals as a home program every day and 4 sessions a day during 6 weeks.
Study: NCT05753696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan
Description: Azilsartan initial dose 20mg/d, if not reached the goal of hypertension; azilsartan dose 40mg/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: losartan initial dose 40mg/d, if not reached the goal of hypertension; losartan 100mg/d
Study: NCT04749004

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promotion of physical activity
Description: Provision of motivational stimuli (commitment contracts, nudges, financial incentives) to increase amount of steps taken
Study: NCT06070961

Intervention type: DIAGNOSTIC_TEST
Intervention: Cellular immunity vs SARS-CoV-2
Description: Evaluation of cellular immunity vs SARS-CoV-2 by ELISpot assay

Intervention type: DIAGNOSTIC_TEST
Intervention: Humoral immunity vs SARS-CoV-2
Description: Evaluation of Humoral immunity vs SARS-CoV-2 by ELISA assay (IgG anti-RBD and anti-N)

Intervention type: DIAGNOSTIC_TEST
Intervention: Cellular immunity vs Varicella Zoster Virus
Description: Evaluation of cellular immunity vs VZV by Enzyme-Linked immunoSPOT (ELISPOT) assay

Intervention type: DIAGNOSTIC_TEST
Intervention: Humoral immunity vs Varicella Zoster Virus
Description: Evaluation of humoral immunity vs VZV by ELISA (VZV gE-binding IgG)

Intervention type: DIAGNOSTIC_TEST
Intervention: Diphtheria toxin-binding IgG
Description: Evaluation of diphtheria toxin-binding IgG by ELISA assay

Intervention type: DIAGNOSTIC_TEST
Intervention: Tetanus toxoid-binding IgG
Description: Evaluation of tetanus toxoid-binding IgG by ELISA assay

Intervention type: DIAGNOSTIC_TEST
Intervention: T-cell populations and markers characterization
Description: Characterization of T-cell populations and markers by flow cytometry
Study: NCT05298553

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group A
Description: Participants will be asked to perform a simultaneous 30-seconds 12-lead ECG and single-lead ECG for each wearable device: Skylab CART-I ring followed by Apple Watch.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group B
Description: they will be asked to perform a simultaneous 30-seconds 12-lead ECG and single-lead ECG for each wearable device: Apple Watch followed by the Skylab CART-I ring.
Study: NCT05155267

Intervention type: OTHER
Intervention: Biomonitoring study to detect MNPLs in biological samples and study of their health effects
Description: Determination of MNPLs levels, genotoxic damage and immunological effects

Intervention type: OTHER
Intervention: Biomonitoring study to detect MNPLs in biological samples and study of their health effects
Description: Determination of MNPLs levels, genotoxic damage and immunological effects

Intervention type: OTHER
Intervention: Biomonitoring study to detect MNPLs in biological samples and study of their health effects
Description: Determination of MNPLs levels, genotoxic damage and immunological effects
Study: NCT04373252

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMT Lower Delivery (FMP 30)
Description: Participants will receive two fecal microbiota transplants via antegrade enema, one week apart.
Study: NCT04857632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin
Description: atorvastatin 20mg per day for 7 days
Study: NCT05761548

Intervention type: DIAGNOSTIC_TEST
Intervention: ultrafast ultrasound power Doppler imaging
Description: ultrafast ultrasound power Doppler imaging for neonatal brain microvessels

Intervention type: DIAGNOSTIC_TEST
Intervention: ultrafast ultrasound power Doppler imaging
Description: ultrafast ultrasound power Doppler imaging for neonatal brain microvessels
Study: NCT05401097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV or SC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy of the bone marrow

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy of the bone marrow

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT06441240

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Breast MRI
Study: NCT06356896

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diaphragmatic breathing exercise
Description: Each patient's relative should not be in the room, the curtains/screens around the patient bed should be closed, and interventions should be applied in a comfortable environment care will be taken to ensure that the room is quiet and calm. During the first 5 minutes, researchers will explain with pictures how the exercise is done and show it to the patient. The patient will then be asked to perform the exercise for 10 minutes under the supervision of the researchers. If the patient has performed the DBE correctly, the procedure will be discontinued. Otherwise, the patient will be asked to practice for another 5 minutes. If at the end of this period the patient still cannot perform the exercise correctly, he will be removed from the sample. DBE will be performed according to Cleveland Clinic guidelines.
Study: NCT04693624

Intervention type: OTHER
Intervention: Hormonal levels
Description: A total of ten (10) blood samples (2ml/each) will be collected during the study for subsequent analysis of progesterone, hCG, inhibin-A, and 17-OH-progesterone:~Day of triggering (before the injection of hCG, appx. 6 pm) Twelve (12 hours) after hCG injection (appx. at 6 am) Twenty-four (24) hours after hCG injection (appx. at 6 pm) Thirty-six (36) hours after hCG injection (appx. at 8 am, 2 hours after OPU) One (1) day after OPU (60h after hCG) (appx. at 6 am) Two (2) days after OPU (84h after hCG) (appx. at 6 am) Three (3) days after OPU 108h after hCG) (appx. at 6 am) Four (4) days after OPU (132h after hCG) (appx. at 6 am) Five (5) days after OPU (156h after hCG) (appx. at 6 am) Six (6) days after OPU (180h after hCG) (appx. at 6 am)
Study: NCT05008965

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FB825
Description: A humanized monoclonal immunoglobulin G1 (IgG1) targeting the CεmX domain on human B lymphocytic cells expressing membrane-bound IgE (mIgE).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Formulation buffer
Study: NCT05346419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risedronate
Description: Participants received risedronate 35 mg once a week for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Participants received 2,800 IU of vitamin D once a week, with additional daily supplementation of 4,000 IU of vitamin D
Study: NCT05556044

Intervention type: DRUG
Group type: OTHER
Intervention: Empagliflozin 10 MG
Description: This is an investigator-initiated, prospective, single-centre, non-randomized open label study that evaluates the efficacy and safety of initiating empagliflozin during index hospitalization for acute heart failure regardless of LVEF.
Study: NCT06045702

Intervention type: PROCEDURE
Intervention: Epididymal sample
Description: During a planned surgical procedure carried out by the Urology and Medically Assisted Reproduction (MAP) department at Brest University Hospital in the patients included in the study, a remnant epididymal sample (between ½ and ¼ of a cc) will be kept for research purposes. These patients suffer from male infertility, leading them to undergo surgery in order to check for the presence of spermatozoa in the epididymis, and to recover spermatozoa which will be frozen and flaked in the AMP department of the CHU Brest, in the event of future procreation by in vitro fertilisation.

Intervention type: PROCEDURE
Intervention: Epididymal sample
Description: During a planned surgical procedure carried out by the Urology and Medically Assisted Reproduction (MAP) department at Brest University Hospital in the patients included in the study, a remnant epididymal sample (between ½ and ¼ of a cc) will be kept for research purposes. These patients suffer from male infertility, leading them to undergo surgery in order to check for the presence of spermatozoa in the epididymis, and to recover spermatozoa which will be frozen and flaked in the AMP department of the CHU Brest, in the event of future procreation by in vitro fertilisation.
Study: NCT04029077

Intervention type: OTHER
Intervention: NA: intervention is not part of the study
Description: NA: it is not an interventional study